GSK and Flagship Pioneering Join Forces to Discover Novel Therapeutics and Vaccines
Shots:
- GSK & Flagship Pioneering have partnered to discover & develop new therapies & vaccines for respiratory & immunology diseases by combining GSK’s knowledge in disease areas & development with Flagship’s ecosystem of bioplatform companies (incl. new modalities & tech)
- Both will invest ~$150M upfront to explore promising concepts for R&D through Flagship’s bioplatform companies, building a portfolio of 10 novel therapies & vaccines; GSK gets exclusive option for further advancement of these candidates
- Flagship & its bioplatform companies will obtain ~$720M upfront, development & commercial milestones plus preclinical funding & tiered royalties for each acquired candidate
Ref: GSK | Image: GSK & Flagship Pioneering
Related News:- Flagship Pioneering and ProFound Therapeutics Team Up with Pfizer to Discover Novel Therapies to Treat Obesity
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
